21 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 34339801 | Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance. | 2021 Nov 1 | 2 |
2 | 34445279 | Secretory NPC2 Protein-Mediated Free Cholesterol Levels Were Correlated with the Sorafenib Response in Hepatocellular Carcinoma. | 2021 Aug 9 | 1 |
3 | 32434082 | Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma. | 2020 Jul 15 | 1 |
4 | 33021963 | MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression. | 2020 Sep 21 | 1 |
5 | 28053052 | ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis. | 2018 Apr | 1 |
6 | 29196297 | Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers. | 2018 Mar 1 | 1 |
7 | 29463989 | Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. | 2018 | 4 |
8 | 29599330 | Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo. | 2018 Apr | 1 |
9 | 30126548 | Lymphocyte-Specific Protein-1 Controls Sorafenib Sensitivity and Hepatocellular Proliferation through Extracellular Signal-Regulated KinaseĀ 1/2 Activation. | 2018 Sep | 2 |
10 | 28282575 | Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. | 2017 May | 3 |
11 | 28661484 | Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. | 2017 Jun 29 | 1 |
12 | 25418579 | Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model. | 2015 Mar | 1 |
13 | 26287667 | TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. | 2015 Sep 29 | 1 |
14 | 25436606 | Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3. | 2014 | 1 |
15 | 22653837 | Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. | 2012 Dec | 2 |
16 | 22753710 | The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. | 2012 Jul | 3 |
17 | 20015197 | Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. | 2011 Feb | 1 |
18 | 21693435 | cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. | 2011 Aug | 1 |
19 | 19276184 | Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy. | 2009 Mar | 2 |
20 | 19432991 | Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. | 2009 May 11 | 2 |
21 | 19723882 | AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. | 2009 Sep | 4 |